Press Releases

Year

C4 Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx

WATERTOWN, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the

Nov 25, 2020

C4 Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

WATERTOWN, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will present at the

Nov 13, 2020

C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

– Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer – – Completed upsized IPO in October 2020, raising $209.8 million in gross proceeds; cash runway extended into the second

Nov 12, 2020

C4 Therapeutics to Present at the 3rd Annual Targeted Protein Degradation Summit

WATERTOWN, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced that it will present in a talk and

Oct 14, 2020

C4 Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

WATERTOWN, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics , Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the closing of its initial public

Oct 6, 2020

C4 Therapeutics Announces Pricing of an Upsized Initial Public Offering

WATERTOWN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the pricing of its upsized initial public

Oct 1, 2020

Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics

WATERTOWN, Mass.--( BUSINESS WIRE )--C4 Therapeutics (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the hiring of Andrew Hirsch as the Company’s incoming chief executive

Sep 8, 2020

C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

WATERTOWN, Mass.--( BUSINESS WIRE )-- C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M.

Jul 15, 2020

C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-Concept and to Advance Proprietary Platform

-Multiple oncology-focused programs poised to enter clinical trials in 2021 and 2022- WATERTOWN, Mass.--( BUSINESS WIRE )-- C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today

Jun 16, 2020

Press Releases

Press Releases

Who We Are

Research & Technology

Investors

Careers

Press Releases

Press Releases

Toolkit

Who We Are

Research & Technology

Investors

Careers

Social

Legal